

# Present the 13th Annual 2022 Residency Symposium Wednesday, May 11, 2022—5:45PM to 8:30PM Live Online CE Activity for Pharmacists

Program Chair: Jason Bandy, PharmD, FCHSP, FCPhA, Associate Professor and Vice Chair of Experiential Education, CNUCOP Committee Members: Amy Blackburn, PharmD, Dignity Health/CSHP-SV Amanda Byrd, PharmD, APh, BCPS, Dignity Health/CSHP-SV Jennifer Courtney, PharmD CNUOP Andrew Mallen, PharmD, Adventist Health, Ukiah Valley Welly Mente, PharmD, FCHSP, CNUCOP Jeffrey Nehira, PharmD, FCHSP, CNUCOP

Knowledge-based Activity for Pharmacists 0.275 CPE for 2.75 hours of live instruction

CPE Activity #'s Breakout Room #1 0597-0000-22-004-L01-P |Breakout Room #2 0597-0000-22-005-L01-P |Breakout Room #3 0597-0000-22-006-L01-P

No registration fee. | To learn more and register, https://tinyurl.com/mv5taspf

## **Our Pharmacy Resident presenters will be:**

Afua Agyema, PharmD, PGY1 Pharmacy Resident at Sutter Medical Center Ellen Berkley, PharmD, PGY1 Pharmacy Resident at University of California, Davis Medical Center Rajan Bhullar, PharmD, PGY1 Pharmacy Resident at Kaiser Permanente Roseville Raymond Chau, PharmD, PGY1 Pharmacy Resident at Sutter Health East Bay/CNUCOP Liann Hoang, PharmD, PGY1 Pharmacy Resident at Kaiser Permanente Dan Ho, PharmD, MS, PGY1 Pharmacy Resident at Dignity Health – MMSJ/MGH Patrick Huynh, PharmD, PGY1 Pharmacy Resident at Sutter Health East Bay/CNUCOP Haneul Kim, PharmD, PGY1 Pharmacy Resident at Sutter Health East Bay/CNUCOP Aeris Lautchang, PharmD, PGY1 Pharmacy Resident at Kaiser Permanente Roseville Dat Le, PharmD, PGY1 Pharmacy Resident at VA Northern California Health Care System Annette Lee, PharmD, PGY1 Pharmacy Resident at Sutter Medical Center Sacramento Marissa Lin, PharmD, MBA, PGY1 Pharmacy Resident at Envolve Pharmacy Solutions Monica Lomanto, PharmD, PGY1 Pharmacy Resident at VA Northern California Health Care System Danielle Mar, PharmD, PGY1 Pharmacy Resident at VA Northern California Health Care System Shannon Muir, PharmD, PGY1 Pharmacy Resident at Kaiser Permanente South Sacramento Julie Nguyen, PharmD, PGY1 Pharmacy Resident at Adventist Health Lodi Memorial/CNUCOP Marian Saweres, PharmD, PGY1 Pharmacy Resident at Kaiser Permanente South Sacramento Caroline Sun, PharmD, PGY1 Pharmacy Resident at VA Northern California Health Care System



**California Northstate University, College of Pharmacy** is accredited by the Accreditation **Council of Pharmacy Education** as a provider of continuing pharmacy education. In accordance with the Accreditation Council for Continuing Pharmacy Education Standards for Commercial Support, all planners, teachers, and authors involved in the development of CPE content are required to disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be disclosed to the activity audience.



Photo by RF.\_.studio: https://www.pexels.com/photo/person-holding-injection-3825529/

Contact: Joanna.jullien@cnsu.edu



# 2022 Residency Symposium

## You are invited to a live online CE event!

Wednesday, May 11, 2022 – 5:45PM to 8:30PM

No registration fee/<u>Refund policy</u> Registration deadline: May 11, 2022 - Noon

**CPE Activity #'s Breakout Room #1:** 0597-0000-22-004-L01-P **Breakout Room #2:** 0597-0000-22-005-L01-P **Breakout Room #3** 0597-0000-22-006-L01-P

### **REGISTER HERE:** <u>https://tinyurl.com/mv5taspf</u>

#### (Important: Your RSVP is not registration. To receive zoom access, please register.)

Activity type: Knowledge

Venue: Zoom (to access Zoom provided after registration).

**CPE Credit information:** This activity is eligible for 0.275 CPE for 2.75 hours of live instruction. **No partial credit.** 

**Threshold of Participation:** To earn CE credit, you must attend all presentations in your chosen or assigned breakout room and complete the pre- and post -activity tests and evaluations.

**Breakout Room Assignments:** Upon registration (see link above) you will be offered the option to select the Breakout Room you wish to be assigned. The list of presenters and topics for each breakout room is below.

## **Program Overview:**

#### $5{:}45PM$ to $6{:}00PM-Welcome$ /Accreditation & Program Overview

#### 6:00PM to 8:00PM – Presentation Breakout Rooms

6:00 - 6:10PM Take the pre-activity test of all presentations in your breakout room

6:10 – 8:10PM Presentations by six speakers per zoom breakout room

 $8{:}10-8{:}25PM$  Access the Post-Activity Test and Evaluation form.

8:25PM to 8:30PM – Closing Remarks

### Breakout Room #1: Topics, Speakers and Learning Objectives Activity #: 0597-0000-22-004-L01-P

**Topic:** Genitourinary Infection Risk in Patients with HIV Taking SGLT2 Inhibitors **Presenter:** Marian Saweres, PharmD – PGY1 Pharmacists Resident at Kaiser Permanente South Sacramento

#### Learning Objectives:

- Explain the mechanism of action of sodium glucose cotransporter-2 (SGLT2) inhibitors
- Describe the incidence of (GU) infection in patients with human immunodeficiency virus (HIV) and type 2 diabetes mellitus (T2DM) taking SGLT2 inhibitors versus patients taking glucagon like peptide-1 (GLP-1) agonists or dipeptidyl peptidase-4 (DPP-4) inhibitors
- Describe the risk of GU infection based on cluster of differentiation 4 (CD4) count stratification between the drug groups.

#### **Topic:** AUC Monitoring Optimizes Vancomycin Dosing

**Presenter:** Julie Nguyen, PharmD, PGY1 Pharmacy Resident, Adventist Health Lodi Memorial/CNUCOP

#### Learning Objectives:

- Identify the impact of AUC-based monitoring compared with trough-based monitoring for vancomycin on the rate of nephrotoxicity.
- Describe patient-specific factors or other variables that may affect the rate of nephrotoxicity. Recognize the incidence of acute kidney injury as defined by Kidney Disease Improving Global Outcomes guidelines.

**Topic:** Initial Heparin Rate For VTE Treatment In Patients On Factor Xa Inhibitors **Presenter:** Patrick Huynh, PharmD, PGY1 Resident Sutter Health East Bay Oakland **Learning Objectives:** 

- Explain the ambiguity surrounding the initial dosing of unfractionated heparin for treatment of venous thromboembolism.
- Describe how to effectively transition from Factor Xa inhibitors to unfractionated heparin.
- Describe the outcomes comparing different initial rates of heparin for venous thromboembolism treatment.

**Topic:** Urinary tract infection management in the emergency department **Presenter:** Caroline Sun, PharmD, PGY1 Pharmacy Resident, VA Northern California Health Care System

#### Learning Objectives:

- Describe clinical antimicrobial stewardship interventions that can be used to improve treatment in patients with urinary tract infections in the emergency department
- Recognize IDSA guideline-based recommendations for uncomplicated urinary tract infections and asymptomatic bacteriuria

**Topic**: Effectiveness of "Code Sepsis" Protocol on Antibiotic Administration **Danielle Mar, PharmD**, PGY1 Pharmacist Resident at VA Northern California Health Care System **Learning Objectives:** 

- Explain the difference between the 2018 and 2021 Surviving Sepsis Campaign guidelines on antibiotic timing
- Describe the impact of a protocol in improving time to antibiotic administration for septic patients in the emergency department
- Identify if there are benefits or harms in administering antibiotics within 1 hour compared to within 3 hours

**Topic:** Evaluating Antibiotic Use in Hospitalized COVID-19 Pneumonia Patients **Presenter:** Aeris Lautchang, PharmD, PGY1 Resident Kaiser Permanente Roseville **Learning Objectives:** 

- List the prevalence of antibiotic use, explain when antibiotic use is indicated
- List the prevalence of bacterial co-infection for patients hospitalized with COVID-19
- Describe the association between Antimicrobial Stewardship Program (ASP) pharmacist intervention and antibiotic therapy duration.

## Breakout Room #2: Topics, Speakers and Learning Objectives Activity # 0597-0000-22-005-L01-P

**Topic:** The Impact of a Pharmacist-Driven Transitions of Care Program on 30-Day Readmissions Rates in Patients with Acute Coronary Syndrome **Presenter:** Dan Ho, PharmD, MS – PGY1 Pharmacist Dignity Health – MMSJ/MGH **Learning Objectives:** 

- Explain the Hospital Readmissions Reduction Program (HRRP).
- List the types of interventions made by a transitions of care pharmacist.
- Describe the role of a transitions of care pharmacist in reducing readmissions in patients with acute coronary syndrome.

**Topic:** Does a switch between GLP-1s cause additional A1c lowering effects? **Presenter:** Shannon Muir, PharmD – PGY1 Pharmacist Resident at Kaiser Permanente South Sacramento

#### **Learning Objectives:**

- Describe the A1c and weight loss benefits in switching between GLP-1 agonists
- Identify which GLP-1 agonists demonstrate cardiovascular benefits
- Identify which GLP-1 agonists have been FDA approved for chronic weight management.

**Topic:** Effect of Different Glucocorticoid Dosages in COPD Exacerbation **Presenter:** Haneul Kim, PharmD, PGY1 Resident, Sutter Health East Bay **Learning Objectives:** 

- Discuss current guideline recommendation and supporting evidence of glucocorticoid use in COPD exacerbation
- Identify safe and effective glucocorticoid dose in COPD exacerbation

**Topic:** Impact of a Transitions of Care Program at a Community Hospital **Presenter:** Annette Lee, PharmD, PGY1 Pharmacy Resident, Sutter Medical Center Sacramento **Learning Objectives:** 

- Explain transitional care definitions
- Identify pharmacist-driven strategies to optimize transitional care at hospital discharge
- Evaluate the impact of a transitional care program through quality metrics and outcomes

**Topic:** Analyzing the Conversion of Symbicort to Wixela in a Veteran Population **Presenter: Dat Le, PharmD**, PGY1 Pharmacist Resident at VA Northern California Health Care System

#### **Learning Objectives:**

- Describe the cost avoidance from a medication conversion process.
- Outline areas for improvement in the conversion process at VA Northern California Health Care System.
- Review reasons for unsuccessful conversions and rates of hospitalizations

**Topic:** Comparison of Hb A1c Reduction with Remote vs Continuous Glucose Monitoring **Presenter:** Liann Hoang, PharmD, PGY1 Resident Kaiser Permanente Roseville **Learning Objectives:** 

- Describe the change in hemoglobin A1c percentage between patients using a remote glucose monitoring device compared to patients using a continuous glucose monitoring device
- List the number of hypoglycemia and hyperglycemia incidents
- List the percentage of patients reaching a hemoglobin A1c goal of < 8% within 6 months after using the remote or continuous glucose monitoring device

## Breakout Room #3: Topics, Speakers and Learning Objectives Activity # 0597-0000-22-006-L01-P

**Topic:** Evaluating Use and Cost of Dupilumab for Atopic Dermatitis **Presenter:** Marissa Lin, PharmD, MBA – PGY1 Pharmacists Envolve Pharmacy Solutions **Learning Objectives:** 

- Explain the differences for dupilumab's initial utilization management among Medicaid, HIM (marketplace), and Commercial lines of business
- Describe the trend of medical and pharmacy costs changes before and after the initiation of dupilumab for the payer

**Topic:** Analysis of Insulin Use in the Emergency Department in Non-DKA, Non-HHS Hyperglycemia

**Raymond Chau, PharmD**, PGY1 Pharmacists Resident at Sutter Health East Bay/CNUCOP Learning Objectives:

- Identify common insulin prescribing patterns for the treatment of nonemergent, acute hyperglycemia within the emergency department
- Evaluate methods that may prevent errors related to insulin use in the emergency department.

**Topic:** Evaluation of treatment outcomes associated with empiric and delayed definitive carbapenem therapy in a tertiary hospital

**Presenter:** Afua Agyema, PharmD, PGY1 Pharmacist Resident Sutter Medical Center **Learning Objectives:** 

- Describe the effect of inappropriate use of antibiotics
- Describe the role of carbapenem in empiric treatment of infections
- Identify the treatment outcomes associated with empiric and definitive carbapenem use

**Topic:** Effectiveness of an Opioid Stewardship Guideline in Renal Transplant Recipients postdischarge at UC Davis Health (UCDH)

**Presenter:** Ellen Berkley, PharmD, PGY1 Resident University of California, Davis Medical Center

#### Learning Objectives:

- Discuss the role of opioids in post renal transplantation pain control
- List some benefits of implementing standardized guidance on pain medication prescribing for post renal transplantation pain management
- Identify barriers to implementing standardized prescribing practices for post renal transplantation pain management
- Describe key stakeholders that support high quality opioid stewardship initiatives

**Topic:** Impact of an Opioid Safety Committee on Veterans in a Primary Care Setting **Presenter:** Monica Lomanto, PharmD, PGY1 Pharmacy Resident at VA Northern California Health Care System

#### **Learning Objectives:**

- Identify the risks of long-term opioid therapy
- Describe the trend in prescribing patterns of opioids and benzodiazepines after Opioid Safety Committee discussions.

#### Rajan Bhullar, PharmD, PGY-1 Pharmacist Resident, Kaiser Permanente Roseville

Topic: Hypersensitivity Reaction Rates with First-Dose Taxane Line Priming

#### Learning Objectives:

- Describe how priming the intravenous line with drug as compared to priming with diluent potentially impacts hypersensitivity reaction rates in first-dose taxanes.
- Describe the relationship between demographic variables and incidence of hypersensitivity reactions with first-dose taxanes. List the time of onset to hypersensitivity reactions. Describe the severity of hypersensitivity reactions.

#### **Technical Requirements**

- Zoom Access System Requirements for Windows, MacOS, and Linux: <u>https://bit.ly/3doVTcJ</u>
- If you have any questions or require additional assistance, please contact: joanna.jullien@cnsu.edu

#### Grievance Procedure/Tell Us What Happened: https://forms.gle/GAfNfroDp7y3SQQb6

#### Accreditation and Disclosures:

California Northstate University, College of Pharmacy is accredited by the Accreditation Council of Pharmacy Education as a provider of continuing pharmacy education. In accordance with the Accreditation Council for Continuing Pharmacy Education Standards for Commercial Support, all planners, teachers, and authors involved in the development of CPE content are required to disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be disclosed to the activity audience.

\*\*\*

If you have any questions or require additional assistance, please contact: Joanna Jullien, joanna.jullien@cnsu.edu, 916-686-7891/Office of Academic Affairs

Looking forward to seeing you there!

Joanna Jullien CNU Director of CE Programs/Office of Academic Affairs California Northstate University/9700 West Taron Drive, Elk Grove, CA 95757



Thank you for your participation.